JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hojo, M.
Right arrow Articles by Martin, J. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hojo, M.
Right arrow Articles by Martin, J. G.

Vol. 293, Issue 2, 410-416, May 2000

Role of Cysteinyl Leukotrienes in CD4+ T Cell-Driven Late Allergic Airway Responses1

Masayuki Hojo, Masaru Suzuki, Karim Maghni2, Qutayba Hamid, William S. Powell and James G. Martin

Meakins-Christie Laboratories, Royal Victoria Hospital, McGill University, Montreal, Quebec, Canada

Cysteinyl leukotrienes (cys LTs) play an important role in late responses to allergen challenge of actively sensitized rats. The aim of this study was to determine whether T cell-dependent late airway responses (LARs) also are mediated by cys LTs. To do this we tested the effects of the selective and potent LTD4 antagonist pranlukast on airway responses to ovalbumin (OVA) challenge of naive recipients of CD4+ T cells isolated from the cervical lymph nodes of OVA-sensitized donor rats. CD4+ T cells (5 million) were purified by immunomagnetic separation and administered i.p. 2 days before OVA challenge. The pulmonary resistance was measured for 8 h after challenge and bronchoalveolar lavage (BAL) was performed for analysis of leukocytes and major basic protein-positive cells. The LAR, determined as the area under the curve of pulmonary resistance against time from 3 to 8 h after challenge, was 8.9 ± 1.79 cm H2O/ml/s × min after OVA compared with 2.8 ± 0.50 cm H2O/ml/s × min (P < .01) after OVA and pranlukast treatment. The total cell count in BAL was not significantly greater in the OVA challenged group (3.55 ± 0.41 × 106 cells) compared with the OVA- and pranlukast-treated group (2.65 ± 0.45 × 106 cells). However, lymphocytes and eosinophils were reduced in numbers by pranlukast. Interleukin-5 mRNA-positive cells were diminished by 50% in pranlukast-treated animals. In conclusion, pranlukast inhibits LAR, BAL eosinophilia, and Interleukin-5 expression in rats with adoptively transferred LAR, indicating an important role for cys LTs in these T cell-driven responses.


1 This study was supported by Medical Research Council of Canada Grant 10381 and Smith Kline Beecham (Dr. Thomas Leonard).

2 K. Maghni is a recipient of a fellowship from the Medical Research Council of Canada.


0022-3565/00/2932-0410$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 2000 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
Am. J. Respir. Crit. Care Med.Home page
K. Parameswaran, R. Watson, G. M. Gauvreau, R. Sehmi, and P. M. O'Byrne
The Effect of Pranlukast on Allergen-induced Bone Marrow Eosinophilopoiesis in Subjects with Asthma
Am. J. Respir. Crit. Care Med., April 15, 2004; 169(8): 915 - 920.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
D. RAMOS-BARBÓN, M. SUZUKI, R. TAHA, S. MOLET, T. B. ISSEKUTZ, Q. HAMID, and J. G. MARTIN
Effect of {alpha}4-Integrin Blockade on CD4+ Cell-driven Late Airway Responses in the Rat
Am. J. Respir. Crit. Care Med., January 1, 2001; 163(1): 101 - 108.
[Abstract] [Full Text]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2000 by the American Society for Pharmacology and Experimental Therapeutics.